HighField Biopharmaceuticals Announces First Patient Dosed in Phase 1b/2 Trial of HF1K16 for Recurrent and Refractory Glioma
HF1K16 is a new immuno-oncology drug targeting myeloid-derived suppressor cells (MDSC) to treat cancer HighField Biopharmaceuticals a clinical stage immuno-oncology company using immunoliposomes to treat cancer, announced today the first patient has been dosed in a Phase 1b/2 trial of HF1K16 for recurrent and refractory glioma. HF1K16 is a drug encapsulated immune modulating liposome containing all-trans retinoic acid (ATRA).
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
